Disease Burden and Conditioning Regimens in ASCT1221, A Randomized Phase II Trial in Children with Juvenile Myelomonocytic Leukemia: A Children’s Oncology Group Study

BACKGROUND: Most patients with juvenile myelomonocytic leukemia (JMML) are curable only with allogeneic hematopoietic cell transplantation (HCT). However, the current standard conditioning regimen, busulfan-cyclophosphamide-melphalan (Bu-Cy-Mel), may be associated with higher risks of morbidity and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Dvorak, Christopher C., Satwani, Prakash, Stieglitz, Elliot, Cairo, Mitchell S., Dang, Ha, Pei, Qinglin, Gao, Yun, Wall, Donna, Mazor, Tali, Olshen, Adam B., Parker, Joel S., Kahwash, Samir, Hirsch, Betsy, Raimondi, Susana, Patel, Neil, Skeens, Micah, Cooper, Todd, Mehta, Parinda A., Grupp, Stephan A., Loh, Mignon L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5980696/
https://ncbi.nlm.nih.gov/pubmed/29528181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.27034
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados